Paul Berns is Chief Executive Officer of Neumora Therapeutics, Inc. (NMRA). The company reported total compensation of $4,562,461 for fiscal year 2025.
| Salary | $700,000 |
|---|---|
| Bonus | $21,000 |
| Stock awards | $0 |
| Option awards | $3,326,181 |
| Non-equity incentive plan | $504,000 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $11,280 |
| Total | $4,562,461 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Neumora Therapeutics, Inc. filed April 17, 2026, accession 0001193125-26-161489.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer | $700,000 | $21,000 | $0 | $3,326,181 | $504,000 | $0 | $11,280 | $4,562,461 |
| FY2024 | Chief Executive Officer | $470,000 | $0 | $3,094,488 | $4,818,975 | $253,800 | $0 | $11,130 | $8,648,393 |
Totals as disclosed in each year's own compensation disclosure for Neumora Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Paul Berns this page | Chief Executive Officer | $4,562,461 |
| Henry Gosebruch | Former President and Chief Executive Officer | $1,319,273 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Neumora Therapeutics, Inc. compensation brief.
Paul Berns's compensation sits inside Neumora Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.